ClinicalTrials.gg
CompletedNCT00882362Updated Feb 10, 2014Results posted

Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

A Phase 3 interventional study of OPC-14597 (Aripiprazole) in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
155
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.

Enrollment
18th of 33
155 · median 173
Started
2009
with 2 others
Phase 3
13 of 33
none open now
Registered
10th of 33
by date
Lead sponsor
2 of 33
Otsuka Pharmaceutical Co., Ltd.

Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 18th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 10th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing aripiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor (SNRI), in subjects with major depressive disorder.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are either inpatients or outpatients
  2. Patients who have the ability to understand and to provide to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial
  3. Patients diagnosed as having either "296.2x Major Depressive Disorder, Single Episode" or "296.3x Major Depressive Disorder, Recurrent" according to , and for whom the current episode of major depressive disorder has been ongoing for more than 8 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Female patients of child bearing potential who wish to become pregnant during the treatment period, or within 4 weeks after study completion/discontinuation
  2. Female patients who are pregnant, possibly pregnant, or breast feeding
  3. Patients judged to be unable to tolerate any type of antidepressant treatment (including drugs not being used in the current episode of major depressive disorder), based on treatment history to date
  4. Patients who have previously received electro-convulsive therapy
  5. Patients who have participated in clinical studies on medical devices or other drugs within the past month
  6. Patients at risk of having serious adverse events or developing symptoms that could interfere with safety and efficacy evaluations (such as symptoms of fibromyalgia syndrome overlapping with symptoms of depression), based on previous medical history
  7. Patients with a history or a complication of diabetes
  8. Patients with thyroid disease (excluding patients who are stabilized on drug therapy for at least 3 months)
  9. Patients with a history of serotonin syndrome or psychotropic neuroleptic malignant syndrome
  10. Patients with a history of seizure disorder (epilepsy etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    1

    Drug: OPC-14597 (Aripiprazole)

Interventions

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    Change from baseline to Last Observation Carried Forward (LOCF). Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts

    Time frame: Baseline(Day 1), Week52 or at discontinuation

07

Results

Posted Feb 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneContinuing SubjectsNewly Entering Subjects
Started12233
Completed7310
Not completed4923
Withdrew: Adverse event1310
Withdrew: Withdrawal by subject1310
Withdrew: Lack of efficacy30
Withdrew: Protocol violation72
Withdrew: Pregnancy10
Withdrew: Physician decision51
Withdrew: Diabetic glucose level or hba1c>=6.5%20
Withdrew: Change of residence or other commitments50

Outcome measures

PrimaryMontgomery-Asberg Depression Rating Scale (MADRS)

Change from baseline to Last Observation Carried Forward (LOCF). Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts

Time frame:
Baseline(Day 1), Week52 or at discontinuation
Reported as:
Mean · Rating Score
Montgomery-Asberg Depression Rating Scale (MADRS)
Rating ScoreContinuing SubjectsNewly Entering Subjects
Montgomery-Asberg Depression Rating Scale (MADRS)-4.60 ± 0.8-10.5 ± 1.9

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Continuing Subjects—2/122 (1.6%)111/122 (91%)
Newly Entering Subjects—4/33 (12.1%)29/33 (87.9%)
Most frequent serious events
Most frequent serious events
EventContinuing SubjectsNewly Entering Subjects
Gastrointestinal HaemorrhageGastrointestinal disorders0/1221/33
PneumoniaInfections and infestations0/1221/33
Urinary Tract InfectionInfections and infestations0/1221/33
Femur FractureInjury, poisoning and procedural complications0/1221/33
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1221/33
ParkinsonismNervous system disorders0/1221/33
Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders0/1221/33
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1221/33
Haematoma SubduralInjury, poisoning and procedural complications1/1220/33
Abortion MissedPregnancy, puerperium and perinatal conditions1/1220/33
Most frequent other events
Showing 10 of 27
Most frequent other events
EventContinuing SubjectsNewly Entering Subjects
NasopharyngitisInfections and infestations42/1225/33
Weight IncreasedInvestigations39/1222/33
AkathisiaNervous system disorders34/1228/33
ConstipationGastrointestinal disorders7/1226/33
SomnolenceNervous system disorders14/1225/33
ContusionInjury, poisoning and procedural complications3/1224/33
FallInjury, poisoning and procedural complications0/1224/33
InsomniaPsychiatric disorders6/1224/33
TremorNervous system disorders12/1222/33
DysgeusiaNervous system disorders1/1223/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Continuing SubjectsNewly Entering SubjectsTotal
Mean39.1 ± 8.673.1 ± 5.646.3 ± 16.1
Age, Categorical
Age, Categorical(Participants)Continuing SubjectsNewly Entering SubjectsTotal
<=18 years000
Between 18 and 65 years1220122
>=65 years03333
Sex: Female, Male
Sex: Female, Male(Participants)Continuing SubjectsNewly Entering SubjectsTotal
Female552378
Male671077
Region of Enrollment
Region of Enrollment(participants)Continuing SubjectsNewly Entering SubjectsTotal
Japan12233155
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2009
First posted
Apr 16, 2009
Start
Mar 2009
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Feb 10, 2014
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00882362
Responsible party
Sponsor
First posted
Apr 16, 2009
Start date
Mar 2009
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Feb 10, 2014
Last update
Feb 10, 2014

Study contacts

Katsuhisa Saito
study director · OPC-J

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion